Emergent BioSolutions Announces Commencement Of Phase I Clinical Trial For Monoclonal Antibody To Treat Inhalational Anthrax

Links shared publicly online about this topic.

  • 884
    total visits

Emergent BioSolutions Announces Commencement Of Phase I Clinical Trial For Monoclonal Antibody To Treat Inhalational Anthrax

medicalnewstoday.com —

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's

View full resource at medicalnewstoday.com

Tags: Anthrax, Clinical Trial

  • Share

Most Recently Shared on September 13, 2010 at 6:15 pm By:

Disease_Infect Infectious Disease

Emergent BioSolutions Announces Commencement Of Phase I Clinical Trial For Monoclonal Antibody To Treat Inhalation... http://bit.ly/9EvRkX

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Bio-Terrorism MNT Bio-Terrorism

MNT Clinical Trials MNT Clinical Trials

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

news-medical.net — “Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.” View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on September 8, 2010 at 12:15 pm By:

NewsMedical News-Medical.Net Health News

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic: Emergent BioSo... http://bit.ly/dhZ4Ea

2 years ago...

Reply

Retweet

Favorite

Advertisement